Your browser doesn't support javascript.
loading
Temporal Dynamics of Host Immune Response Associated With Disease Severity and Time to Recovery in Patients Hospitalized for COVID-19.
Sophonsri, Anthony; Le, Diana; Lou, Mimi; Ny, Pamela; Minejima, Emi; Chambliss, Allison B; Nieberg, Paul; Shriner, Kimberly; Wong-Beringer, Annie.
Afiliación
  • Sophonsri A; Department of Clinical Pharmacy, University of Southern California, School of Pharmacy, Los Angeles, CA.
  • Le D; Department of Clinical Pharmacy, University of Southern California, School of Pharmacy, Los Angeles, CA.
  • Lou M; Department of Pharmacy, Huntington Hospital, Pasadena, CA.
  • Ny P; Department of Clinical Pharmacy, University of Southern California, School of Pharmacy, Los Angeles, CA.
  • Minejima E; Department of Pharmacy, Huntington Hospital, Pasadena, CA.
  • Chambliss AB; Department of Clinical Pharmacy, University of Southern California, School of Pharmacy, Los Angeles, CA.
  • Nieberg P; Department of Pathology, University of Southern California, Keck School of Medicine, Los Angeles, CA.
  • Shriner K; Department of Medicine-Infectious Diseases, Huntington Hospital, Pasadena, CA.
  • Wong-Beringer A; Department of Medicine-Infectious Diseases, Huntington Hospital, Pasadena, CA.
Crit Care Explor ; 4(9): e0760, 2022 Sep.
Article en En | MEDLINE | ID: mdl-38371947
ABSTRACT

OBJECTIVES:

The objective of this study was to compare the temporal dynamics of two viral-induced inflammatory proteins interferon gamma inducible protein-10 (IP-10) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), as well as C-reactive protein (CRP) among patients hospitalized for COVID-19 and examine their prognostic significance.

DESIGN:

Prospective observational cohort study.

SETTING:

Multicenter, inpatient. PATIENTS Adult patients infected with severe acute respiratory syndrome coronavirus 2 between March 2021 and October 2021.

INTERVENTIONS:

Patient sera were collected on days 1, 3, 5, and 7 of hospitalization. Levels of IP-10, TRAIL, and CRP were measured using a point-of-need diagnostic immunoassay platform (MeMed BV, MeMed, Haifa, Israel) and compared between patients grouped by disease severity (severe vs nonsevere). MEASUREMENTS AND MAIN

RESULTS:

Baseline characteristics were similar regardless of severity except for a higher prevalence of diabetes and heart failure among severe patients. The immune profile at admission was similar between groups; IP-10 and CRP levels generally decreased while TRAIL levels increased over time in all patients. However, the severe group had higher IP-10 (median 713 vs 328 pg/mL; p = 0.045) and lower TRAIL levels (median 21 vs 30 pg/mL; p = 0.003) on day 3 compared with nonsevere patients. A breakpoint IP-10 level of greater than or equal to 570 pg/mL and TRAIL level of less than 25 pg/mL on day 3 were associated with COVID-19 severity. Patients with elevated day 3 IP-10 levels (≥ 570 pg/mL) were more likely to experience prolonged recovery time (median 12 vs 3 d; p < 0.001). The severe group had prolonged use of corticosteroids (12 vs 5 d; p < 0.001) and had a higher rate of secondary infections (20% vs 6%; p = 0.04) and in-hospital mortality (20% vs 0%; p < 0.001) as compared with nonsevere patients.

CONCLUSIONS:

The observed patterns in host immune response revealed a turning point in COVID-19 disease on hospital day 3 and the potential utility of IP-10 and TRAIL as sensitive markers associated with disease severity and time to recovery.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Crit Care Explor Año: 2022 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Crit Care Explor Año: 2022 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA